Test purchases were completed from 6 illegal online pharmacies with the highest number of links offering semaglutide products for sale without prescription at the lowest price range. Three injection vial purchases were delivered; none of the 3 Ozempic prefilled injection pens were received due to nondelivery e-commerce scams. All purchased vials were considered probable substandard and falsified products, as visual inspection indicated noncompliance in more than half (59%-63%) of the evaluated criteria. The semaglutide content of samples substantially exceeded labeled amounts by 28.56%-38.69%, although no peptide-like impurities were identified. The lyophilized peptide samples were devoid of viable microorganisms at the time of testing; however, endotoxin was detected in all samples with levels ranging between 2.1645 EU/mg and 8.9511 EU/mg. Furthermore, the measured semaglutide purity was significantly low, ranging between 7.7% and 14.37% and deviating from the 99% claimed on product labels by manufacturers.
Of course, probably not representative of the best ranked suppliers, but it does show what is out there and being sold…
And my concern is that even the testing groups out there don’t check very often for:
It’s a tough call to make. As @LukeMV said, you can get a COA showing 99.955 %purity. But that LC-UV-MS test is only detecting peptides and other organic molecules (basically anything that can absorb at 220nm). That LC-UV-MS test does NOT detect any metals like Pb or Cd nor does it detect endotoxin.
Also, a peptide with the same amino acids but in a slightly different order (scrambled) would elute in the same LC peak and be detected as the desired peptide but likely not have the desired biological activity (so it looks like high purity but is not).
In the end, life has risks and we all perform risk assessments every day (“can I fit my car between those two?? I"m in a hurry…”). Just recognize that by using grey market peptides vs FDA approved ones, you are taking on more risk.
Interestingly that is not a straight forward assessment of risk vs harm.
Risk and harm are two very different things.
While total EU/mg is important in determining risk, harm requires taking into account how the product is administered and at what dose per Kg of body weight, per hour, with the EU level in question.
64kg human (like myself) is indicated as tolerating 5 EU/kg = 320 EU total PER HOUR
Using a mid range number from the above test example = 5.2 EU per mg
If I inject 2.4 mg of the “black market” Ozempic peptide with that number, I’m exposed to 13 EU in one dose.
2.4mg once per week is the max dose used, as per the mfg,
If we use the worst case exposure - 8.9511 EU/mg x 2.4mg = 21.48264 EU still significantly below the upper limit for a 64kg human of 320EU, PER HOUR.
Both mid range and worst case findings are significantly below the upper risk level.
Practical summary for “safe” levels
For human drugs, a level is considered “safe” if the total patient exposure per dose per hour does not exceed:
5 EU/kg for most parenteral routes.
0.2 EU/kg for intrathecal/epidural routes.
You translate these exposure caps into EU/mL, EU/mg, or EU/Unit using the maximum dose (M) via K/M and then set your release/specification criteria accordingly
You really can’t predict that…I mean, there are online tools and calculators but its complicated. The LC (or HPLC) is pushing the peptides thru a column filled with C18 resin…they are eluting according to their hydrophobicity/hydrophillicty. Scrambled peptide would like have the same or very similar hydrophobicity.
I decided to run this 2024 paper through my Gemini Pro paper analysis prompt. I wish they’d do a similar paper with a focus on the top vendors as identified on Finnrick.
Results:
The Wild West of Weight Loss: Online Pharmacies and Peptides in the Unregulated Semaglutide Market
Impact Evaluation: The impact score of this journal is 6.0, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.
Executive Summary
The global obesity epidemic and the rise of glucagon-like peptide 1 (GLP-1) agonists have created a highly lucrative environment for pharmaceutical fraud. Semaglutide, legally marketed under brand names like Ozempic and Wegovy, is facing severe international shortages driven by surging off-label demand for cosmetic weight loss. This persistent gap in the legitimate supply chain is rapidly being filled by unregulated online pharmacies and underground peptide vendors seeking to capitalize on high consumer demand.
In a comprehensive market surveillance study, researchers scraped 1080 search engine results for semaglutide products and identified 59 unique illegal online pharmacies. Web traffic analytics revealed that domains linked to these rogue pharmacies amassed over 4.7 million visits between July and September 2023. To evaluate physical and financial risks, investigators conducted targeted test purchases from six high-visibility, high-risk vendors offering semaglutide at low prices without prescription verification.
The operational data exposes a market rife with deceit. Half of the transactions resulted in outright financial scams, utilizing nondelivery schemes and fraudulent customs fee extortions to steal from buyers. The remaining three vendors shipped lyophilized peptide vials that completely failed fundamental safety and pharmaceutical quality standards. Visual package inspections revealed noncompliance in up to 64% of International Pharmaceutical Federation criteria, legally categorizing the products as substandard and falsified.
More critically, quantitative testing via liquid chromatography-mass spectrometry demonstrated alarming chemical discrepancies. While vendor labels aggressively marketed 99% purity, actual semaglutide peptide purity ranged between a dismal 7.7% and 14.37%. Concurrently, the total mass of the active ingredient per vial exceeded the labeled dose by 28.56% to 38.69%, introducing a massive risk of accidental overdose and severe adverse events. Microbiological assays also detected bacterial endotoxins (up to 8.9511 EU/mg) in all delivered samples, indicating unsanitary manufacturing environments. Purchasing grey-market semaglutide currently guarantees exposure to financial fraud, uncharacterized chemical impurities, or systemic inflammatory triggers.
Technical Biohacker Analysis
Study Design Specifications:
Type: Market Surveillance, Content Analysis, and Qualitative/Quantitative Quality Assessment (In vitro chemical and microbiological analysis).
Legitimate GLP-1 receptor agonists like semaglutide indirectly modulate primary longevity pathways . By enhancing insulin sensitivity and reducing circulating glucose, they downregulate the mTOR pathway and stimulate AMPK, which subsequently upregulates cellular autophagy and improves mitochondrial dynamics.
The organ-specific aging priorities for GLP-1 optimization are focused on cardiovascular tissue protection, endothelial function, and pancreatic beta-cell preservation.
However, the critical mechanistic finding from this paper is the detection of bacterial endotoxins in all evaluated grey-market peptide samples. Chronic exposure to endotoxins activates Toll-like receptor 4 (TLR4) and triggers the cGAS-STING pathway, resulting in robust NF-κB-mediated systemic inflammation [Confidence: High]. Subcutaneous injection of these contaminated peptides will induce chronic low-grade inflammation (inflammaging), which actively counteracts the longevity benefits of AMPK/mTOR modulation and directly accelerates cardiovascular and renal aging pathways. [Confidence: High]
Novelty:
Previous assumptions within the biohacking community held that unregulated “research-grade” peptides were mostly pure but lacked strict regulatory oversight. This paper provides empirical analytical data proving that grey-market semaglutide purity is catastrophically low (7.7%–14.37%).
It demonstrates that grey-market vendors aggressively overdose total semaglutide content (by up to 38.69%) to compensate for poor purity, creating erratic and dangerous dosing pharmacokinetics for users attempting self-administration.
Critical Limitations:
Translational Uncertainty & Sample Size: The sample size is practically non-existent for broad statistical extrapolation. N=6 purchases, with only N=3 actual physical analyses. This cannot reliably represent the entire scope of the underground peptide market. [Confidence: High]
Selection Bias: The researchers exclusively evaluated high-risk, clearnet vendors strictly under $200 that did not require prescriptions and shipped only to the US or Hungary. High-end concierge compounding pharmacies or deep-web sources were completely excluded. [Confidence: High]
Missing Data: While the LC-MS analysis identified massive purity deficits (showing that 85%+ of the vial mass was unknown), the researchers failed to perform full toxicological profiling to identify these low-mass, weakly ionizing impurities. Without knowing if these impurities are heavy metals, toxic synthesis byproducts, or benign cleavage residues, the definitive physiological toxicity profile remains incomplete. [Confidence: Medium]
Just to summarize what the key unknown variables are that seem to be something I’d want to test for to make sure the product is good, safe and likely effective:
Trifluoroacetic Acid (TFA)
Endotoxins (Lipopolysaccharides)
Dimerization and Aggregation
Heavy Metals
Proper order of amino acids in the peptide (a peptide with the same amino acids but in a slightly different order (scrambled) would elute in the same LC peak and be detected as the desired peptide but likely not have the desired biological activity)
Right now, most of these are untested and unknown on most peptides (please correct me if I’m wrong folks).
If someone is selling peptides and wants to differentiate themselves from the mass of online gray market sellers, testing and validating these variables would seem to be a good start. Perhaps we can encourage Finnrick to also test for these factors to have better qualified rankings. I’ll send them an email.
@RapAdmin perhaps you might want to send a copy of your email to Janoshik. I only mention him because, to the best of my knowledge, he seems to be one of the most famous/trusted testers
Yes, run these tests on the products you’ve actually received from the vendor, meaning product that you have in hand. Any test result sent by the vendor is safety theater. Nothing wrong with safety theater per se, but just know where you’re putting your trust.
Talking with my Chemistry PHD friend about this issue of validating that the amino acid order in the peptide is correct, (and how to test for it) - he guided me towards these approaches, and suggested I’d need to work with the analytical chemistry lab (and get some support form them… these are not entirely standardized tests it seems).
1. Edman Degradation
Mechanism: Edman degradation sequentially removes and identifies one amino acid at a time from the N-terminus of a purified peptide. Under mildly alkaline conditions, the N-terminal amino group reacts with phenylisothiocyanate (PITC) to form a phenylthiocarbamyl (PTC) derivative. Subsequent treatment with an anhydrous acid, typically trifluoroacetic acid (TFA), cleaves the peptide bond of the N-terminal residue, yielding a thiazolinone derivative and leaving the rest of the peptide chain intact. The thiazolinone is extracted and converted into a more stable phenylthiohydantoin (PTH)-amino acid in aqueous acid, which is then identified via High-Performance Liquid Chromatography (HPLC) against known standards.
Strengths:
Provides absolute sequence confirmation, which is highly precise for short peptides (up to 30–50 residues).
Essential for verifying the exact N-terminal identity of recombinantly expressed proteins in biotech quality control.
Limitations:
Inefficiency for large proteins: Yield drops with each cycle (typically 98% efficiency per cycle), leading to background noise that obscures the signal after ~50 cycles.
N-terminal blockage: Completely fails if the N-terminus is chemically modified (e.g., formylation, acetylation, or pyroglutamate formation).
Cannot identify positionally complex Post-Translational Modifications (PTMs) or cross-links efficiently.
2. Mass Spectrometry (MS)
Mechanism: Mass spectrometry has superseded Edman degradation for high-throughput proteomics. It determines sequences by measuring the mass-to-charge ratio () of ionized peptides and their fragments in a gas phase.
Dominance in Biotech:
High Sensitivity: Requires only femtomolar to attomolar amounts of sample.
Throughput & Complexity: Capable of analyzing complex mixtures (e.g., whole-cell lysates) without prior extensive purification.
PTM Identification: The gold standard for mapping PTMs (phosphorylation, acetylation, advanced glycation end-products), which are critical variables in aging and longevity research.
Standard “Bottom-Up” Workflow:
Proteolytic Digestion: Cleave the target protein into manageable peptides using a specific protease (e.g., Trypsin, which cleaves strictly C-terminal to Arg and Lys).
Chromatographic Separation: Separate the complex peptide mixture via liquid chromatography (LC) directly coupled to the mass spectrometer.
Ionization: Volatilize and ionize peptides using Electrospray Ionization (ESI) or Matrix-Assisted Laser Desorption/Ionization (MALDI).
Tandem MS (MS/MS) Fragmentation: Isolate specific peptide precursor ions and fragment them using Collision-Induced Dissociation (CID) or Higher-energy Collisional Dissociation (HCD). This primarily breaks the peptide bonds, generating sequence-specific -ions (N-terminal fragments) and -ions (C-terminal fragments).
Bioinformatic Reconstruction: Match the experimental MS/MS spectra against theoretical spectra generated from protein databases, or use computationally demanding de novo sequencing algorithms when a reference genome is unavailable.
3. Indirect Sequencing via DNA/RNA Sequencing
Mechanism: Deriving the primary structure of a protein by sequencing its corresponding gene or mRNA transcript and utilizing the standard genetic code to computationally translate the nucleotide sequence.
Caveats in Applied Biology:
The “Static” Genome Problem: Fails to capture the dynamic reality of the proteome. It cannot detect alternative splicing variants unless RNA-seq is specifically utilized and properly mapped.
Blind to Maturation: Cannot detect vital proteolytic processing events (e.g., cleavage of signal peptides or pro-hormones).
Blind to PTMs: Offers no data on the ~300 known biological modifications that regulate protein function, stability, and half-life—data essential for developing structural analogs in biopharmaceutical engineering.
4. Hybrid Approaches & The Research Frontier
Modern proteomics relies on multi-omic integration. Combining genetic database searching (genomics/transcriptomics) with high-resolution MS/MS allows for rapid mapping of massive biological systems.
Scholarly Debates & Emerging Frontiers:
A current limitation in the field is the reliance on “bottom-up” MS, which destroys macroscopic protein context. The exact combination of PTMs on a single unbroken protein molecule (its “proteoform”) is lost.
Top-Down Proteomics: Involves ionizing and fragmenting intact proteins. It maps the true proteoform but is severely limited by decreasing ionization efficiency and complex spectral overlaps as protein mass increases.
Single-Molecule Protein Sequencing: Analogous to nanopore DNA sequencing, research is currently active in designing nanopores or using fluorophore-labeled Edman-like degradation to read individual protein molecules. This remains a significant technical challenge requiring highly engineered biological or solid-state pores.
Summary Table: Analytical Profiling of Peptides
Method
Primary Utility
Major Limitations
Edman Degradation
Absolute N-terminal sequence confirmation of purified short peptides.
Blocked by N-terminal modifications; severe yield drop-off for long chains (>50 residues).
Relies heavily on computational reconstruction and databases; susceptible to ion suppression artifacts.
Amino Acid Analysis
Accurate quantitation of total amino acid ratios; determining absolute protein concentration.
Provides no sequence order; specific residues (Trp, Asn, Gln, Cys) are damaged or altered during standard hydrolysis.
Genetic Sequencing
Rapid, high-accuracy prediction of theoretical primary structure.
Completely ignores translational processing, proteolysis, and all post-translational modifications.
Would you like me to detail the specific bioinformatic algorithms and statistical scoring models (e.g., SEQUEST, Mascot, or deep learning tools) used for de novo MS/MS sequence reconstruction?
I heard back from Finnrick on my questions about what they test, and don’t test yet:
Thanks for reaching out and for sharing these important concerns from your community!
Here’s how we currently cover the areas you mentioned:
Endotoxins (LPS): Yes, we offer endotoxin testing as a paid add-on.
Heavy Metals: Yes, we provide heavy metals testing, including a basic FDA 4-panel and more extensive panels on request.
Trifluoroacetic Acid (TFA) and other solvents: We offer solvents testing as a paid add-on.
Dimerization and Aggregation: Our standard peptide testing focuses on identity, purity, and quantity via HPLC, which may not fully detect subtle peptide aggregation or dimerization. We’re exploring expanding capabilities here.
Amino Acid Sequence Accuracy: Our identity testing confirms the peptide’s presence but cannot distinguish scrambled sequences that elute similarly in LC. This is a known challenge industry-wide.
Regarding the “reagent” test you mentioned, that typically refers to our standard panel covering identity, purity, and quantity.
We’re actively working to expand testing options based on feedback like yours, so please keep the suggestions coming!
Note that finnrick is not a lab, more like a lab broker. You need to ask them which labs perform the tests you’re interested in. Lab quality in general varies widely.
Yes - but it’s really hard to tell lab quality. It would seem that Finnrick is the source (purchaser) for a large number of tests, so they would likely have the best idea of quality of the tests (but do they do comparisons - using same sample between multiple labs to check reliability)?
Generally the companies (analytical chemistry labs) who do the most of a given type of test, are going to be the ones that can do it best, and in the most reliable manner. Like anything, the more you do something, the more you’ve standardized the process, and the better the consistency is.
Given this, it would seem that the labs that Finnrick uses, are going to be one of the better labs for doing this, just due to the volume. But perhaps there are other labs that do most of the industry testing in the USA? Does anyone know the top Peptide analytical chemistry labs? I’ll try Google Gemini.
Finnrick wouldn’t know lab quality unless they did comparisons between them; they just assume all labs are created equal. Anyway, this is one of the many reasons most peptide communities don’t trust this company and its ratings.
Here is the list of labs they use :
Mz biolabs
Chromate
Janoshik
BT Labs
TrustPointe
Krause Analytical
The only recommendation I can make is for Janoshik. By volume, they probably do 5-10x of the tests that the rest of the labs in this list do combined. By reputation, they are considered the gold standard.
TrustPointe is also solid, although there are some peptides they cannot test, check with them.
Ok, but how does Finnick manage to do the testing for free then. My understanding is that they offer free testing (basic) you only pay for shipping? Wouldn’t they have to pay a fee (however small) should they use a third party.
On the pro side, perhaps we can get some peptides (though probably not SS-31) from compounding pharmacies in the US (which would seem potentially safer than ordering from some random seller in China). But… we still don’t have any good human data / clinical trials on most of these:
